Neumora Therapeutics

NMRA

Market cap $306M

NMRA Hedge Fund Activity: Q1 2026 in Review

114 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q1 2026, worth a combined $137M — up 22% from $113M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new NMRA positions and 10 closed out — a net gain of 14 holders — while 34 added to existing stakes and 32 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $13.2M. The largest seller was Point72 Asset Management, cutting an estimated $7.96M.

• 114 institutional investors held Neumora Therapeutics (NMRA) as of Q1 2026, up from 102 in Q4 2025.
• Funds reported $137M of Neumora Therapeutics stock for Q1 2026, up 22% quarter-over-quarter.
• 24 funds opened new Neumora Therapeutics positions in Q1 2026 and 10 closed out, a net change of +14 holders.
• The largest Neumora Therapeutics buyer in Q1 2026 was Perceptive Advisors, an estimated $13.2M added.
• The largest Neumora Therapeutics seller in Q1 2026 was Point72 Asset Management, an estimated $7.96M sold.

Based on aggregated 13F filings for Q1 2026.